Fig. 2From: Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancerTornado diagram of pembrolizumab versus chemotherapy in the one-way deterministic sensitivity analysis. P, probability; PD, progressed disease; PFS, progression-free survival; U, utilityBack to article page